Biotech News 7 October 2025

BlackRock’s Big Bet Sends SELLAS Life Sciences (SLS) Stock Soaring – What’s Next for This Biotech?

Key Facts – October 18, 2025 Stock Performance: SLS on a Tear in 2025 SELLAS Life Sciences’ stock has been on a remarkable run this year. Shares have effectively doubled in 2025,

18 October 2025

ATAI Life Sciences Skyrockets on FDA Breakthrough and $130M Cash Infusion

Key Facts – October 18, 2025 Stock Soars on Breakthrough News and Funding Boost ATAI’s stock price surged in the last few days amid a flurry of good news. Shares jumped 17.7%

18 October 2025

Biotech · FDA Approvals · Investment · NASDAQ:ATAI · Pharma News · Stock Market

Disc Medicine (IRON) Stock Soars on FDA Fast-Track News as Analysts Boost Targets

FDA Voucher Ignites IRON Stock Rally Disc Medicine’s stock price (NASDAQ: IRON) spiked dramatically in mid-October 2025 after news of the FDA voucher, vaulting from the mid-$70s to the low-$90s in a

17 October 2025

Biotech · FDA News · Investment · Pharma Industry · Stock Market

Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

RANI Stock Price Explodes on Deal News Rani Therapeutics’ stock price skyrocketed on Friday, Oct. 17, after the company unveiled a major partnership and funding news. In pre-market trade, RANI jumped about

17 October 2025

Biotech · Financial News · Investments · NASDAQ:RANI · Pharmaceuticals · Stock Market

Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Stock Price Rollercoaster in 2025 Adaptimmune’s stock has been on a wild ride this year, with extreme price swings in recent weeks grabbing headlines. After languishing in penny-stock territory for months, ADAP

16 October 2025

Biotech · Company Analysis · Investing · NASDAQ:ADAP · NASDAQ:HTGC · Pharmaceuticals · Stock Market

Biotech Meets Crypto: ENDRA Life Sciences (NDRA) Stock Skyrockets 33% — Analyst Target $50

Stock Performance Over the past few trading days, NDRA moved sharply higher. It closed $6.48 on Oct 10, 2025 stockinvest.us, up modestly from ~$5.75 a week earlier. On Oct. 13, after the

13 October 2025

Biotech · Cryptocurrency · Investment · Market Analysis · NASDAQ:NDRA · Stocks

AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

Stock Performance & Recent Trends AbbVie’s stock closed at $230.88 on Oct. 10, 2025 marketbeat.com. Over the prior five trading days it moved modestly: Oct. 7: $232.83; Oct. 8: $231.24; Oct. 9: $230.69; Oct. 10: $230.50

11 October 2025

Biotech · Financial Analysis · Investing · NYSE:ABBV · Pharmaceuticals · Stock Market

Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Company Overview Protagonist Therapeutics is a clinical-stage biopharma company leveraging peptide technology to create new medicines for rare hematologic conditions and prevalent immunological diseases protagonist-inc.com. Founded in 2008, Protagonist has built its

11 October 2025

Biotech · Clinical Trials · Mergers & Acquisitions · Pharmaceuticals · Stock Market

Bristol Myers Snaps Up Orbital Therapeutics in $1.5B Biotech Power Play

In-Depth Analysis BMS’s acquisition of Orbital Therapeutics marks a deliberate push into autoimmune disease treatment via advanced cell therapy. Orbital, founded in 2022 by leaders in RNA and immunology, has built a

10 October 2025

Biotech · Healthcare Industry · Investment · Mergers & Acquisitions · NYSE:BMY · Pharma News

Turn Therapeutics (TTRX) Skyrockets After Nasdaq Debut – Biotech Breakthrough or Hype?

Company Profile – Background & Leadership Turn Therapeutics, Inc. is a Westlake Village, CA-based biotech company founded in 2015 renaissancecapital.com. The company (formerly named Global Health Solutions, Inc.) officially rebranded to Turn Therapeutics in Sept

9 October 2025

Biotech · Healthcare Innovation · Investment Analysis · IPO · NASDAQ:TTRX · Stock Market

Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Therapy (Target) Indication Status (2025) Current Ownership TECELRA(afamitresgene, targets MAGE-A4) Synovial sarcoma (unresectable/metastatic) FDA approved Aug 2024 biospace.com; ~16 patients treated in launch year nasdaq.com. Sold to US WorldMeds (2025) adaptimmune.com Letetresgene (lete-cel, NY-ESO-1)

8 October 2025

Biotech · Company Analysis · Financial News · Investing · NASDAQ:ADAP · Stock Market

Dyne Therapeutics Skyrockets on Breakthrough Data – Inside the Surge, Financials & 2026 Catalysts

Recent Stock Performance & Surge on Data Dyne Therapeutics’ stock has been on a tear following its latest clinical breakthroughs. Shares jumped 10–11% intraday on October 7, 2025, after the company reported

7 October 2025

Biotech · Clinical Trials · Investment · NASDAQ:DYN · Pharma News · Stock Market

Biotech News 7 October 2025 - 18 October 2025